Medical Treatment of Cushing Disease. New Targets, New Hope

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

This article provides an update on current medical therapies for the treatment of Cushing disease. This information will be of value in determining patients' suitability for certain medical treatments. An approach of combining drugs from the same or different classes could potentially increase the number of patients in whom Cushing can be controlled while minimizing adverse effects, although larger studies are needed. Successful clinical management of patients with Cushing disease remains a challenge.

Original languageEnglish (US)
Pages (from-to)51-70
Number of pages20
JournalEndocrinology and Metabolism Clinics of North America
Volume44
Issue number1
DOIs
StatePublished - Mar 1 2015

Fingerprint

Pituitary ACTH Hypersecretion
Therapeutics
Pharmaceutical Preparations

Keywords

  • Combination therapies
  • Cushing disease
  • LCI699
  • Medical therapy
  • Mifepristone
  • Pasireotide

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)

Cite this

Medical Treatment of Cushing Disease. New Targets, New Hope. / Fleseriu, Maria.

In: Endocrinology and Metabolism Clinics of North America, Vol. 44, No. 1, 01.03.2015, p. 51-70.

Research output: Contribution to journalArticle

@article{78f098c4542541cb9c4506a421e7613c,
title = "Medical Treatment of Cushing Disease. New Targets, New Hope",
abstract = "This article provides an update on current medical therapies for the treatment of Cushing disease. This information will be of value in determining patients' suitability for certain medical treatments. An approach of combining drugs from the same or different classes could potentially increase the number of patients in whom Cushing can be controlled while minimizing adverse effects, although larger studies are needed. Successful clinical management of patients with Cushing disease remains a challenge.",
keywords = "Combination therapies, Cushing disease, LCI699, Medical therapy, Mifepristone, Pasireotide",
author = "Maria Fleseriu",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.ecl.2014.10.006",
language = "English (US)",
volume = "44",
pages = "51--70",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Medical Treatment of Cushing Disease. New Targets, New Hope

AU - Fleseriu, Maria

PY - 2015/3/1

Y1 - 2015/3/1

N2 - This article provides an update on current medical therapies for the treatment of Cushing disease. This information will be of value in determining patients' suitability for certain medical treatments. An approach of combining drugs from the same or different classes could potentially increase the number of patients in whom Cushing can be controlled while minimizing adverse effects, although larger studies are needed. Successful clinical management of patients with Cushing disease remains a challenge.

AB - This article provides an update on current medical therapies for the treatment of Cushing disease. This information will be of value in determining patients' suitability for certain medical treatments. An approach of combining drugs from the same or different classes could potentially increase the number of patients in whom Cushing can be controlled while minimizing adverse effects, although larger studies are needed. Successful clinical management of patients with Cushing disease remains a challenge.

KW - Combination therapies

KW - Cushing disease

KW - LCI699

KW - Medical therapy

KW - Mifepristone

KW - Pasireotide

UR - http://www.scopus.com/inward/record.url?scp=84946239215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84946239215&partnerID=8YFLogxK

U2 - 10.1016/j.ecl.2014.10.006

DO - 10.1016/j.ecl.2014.10.006

M3 - Article

VL - 44

SP - 51

EP - 70

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - 1

ER -